Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

GateMOF Molecular gated Eco-MOFs for anti-cancer drug delivery

Coordinator
Universitat Politecnica De Valencia, Spain
Runs
5 February 2025 to 4 February 2027
Status
Running
EU funding
€165k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101146953

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is a major societal challenge, as reflected by Horizon's Europe mission on cancer and Europe's Beating Cancer Plan. In particular, despite great advances in cancer treatment in recent decades, its treatment still remains a challenge without an effective cure. In 2020 the EU reported around 3 million new cancer cases and more than 1.2 million deaths, and its incidence is expected to increase in Europe due to its aging population.

The standard treatment relies on the systemic administration of chemotherapeutics, which has limited efficacy and causes side effects. To overcome current limitations, GateMOF will develop low-toxicity Molecular Organic Frameworks (MOFs) as advanced nanosystems to tackle cancer. Such Eco-MOFs will be equipped with molecular gates and loaded with anticancer drugs resulting in advanced biocompatible nanosystems with the ability to respond to stimuli present in the tumor intracellular/microenvironment for a selective anticancer drug delivery.

The project combines the unique expertise of the host laboratory (Supramolecular Chemistry and Biotechnology) and the candidate (MOF design and synthesis) to ensure the fulfillment of objectives. The fellow will be trained in advanced nanomaterial preparation with molecular gates to obtain stimuli-responsive MOFs for anti-cancer drug delivery, including training for biological studies for their evaluation in vitro in cells and in vivo in animal models.

Notably, the project will also allow the fellow to gain experience in patenting and tech transfer. Altogether, GateMOF will develop a new therapeutic technology and provide the fellow with complementary scientific and transferable skills with a significant impact toward an independent research career.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Politecnica De ValenciaValenciaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI